Abnormal psychology

Improving Air Quality Reduces Dementia Risk, Multiple Studies Suggest

Monday, July 26, 2021 - 3:00pm

While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.

Key Points: 
  • While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.
  • "But what's exciting is we're now seeing data showing that improving air quality may actually reduce the risk of dementia.
  • Air Quality Improvement May Slow Cognitive Decline and Reduce Dementia Risk in Older U.S. Women
    Although studies have found that improved air quality is associated with better respiratory health and longer life expectancy, it's unknown if improved air quality can also improve brain health.
  • Association of air quality reduction with incident dementia: effects of natural course and hypothetical air pollutant interventions using g-computation.

Break Free from Marijuana Addiction with New 30-Day Online Program

Monday, July 26, 2021 - 1:38pm

An innovative way to overcome marijuana addiction in the comfort of a customer's own home.

Key Points: 
  • An innovative way to overcome marijuana addiction in the comfort of a customer's own home.
  • The CAARE Program is a 30-day step-by-step program that has the tools needed to overcome marijuana addiction.
  • With the CAARE Program, users can follow a proven plan to break free of addiction, intentionally create the life they want, and live every day forward on their own terms.
  • To find out more about the CAARE Program or the highly-rated The Secret Addiction book, please visit www.secretaddiction.org .

The Cake House Using Clinical Prescription Cannabis To Help Veterans Combat PTSD, Chronic Pain

Thursday, July 22, 2021 - 4:56pm

A recent study of 60,000 Iraq and Afghanistan veterans said 13.5 percent of deployed and non-deployed veterans screened positive for PTSD.

Key Points: 
  • A recent study of 60,000 Iraq and Afghanistan veterans said 13.5 percent of deployed and non-deployed veterans screened positive for PTSD.
  • That is why The Cake House is supplying the veteran community with trusted medicine to combat the effects of PTSD, reduce chronic pain, nausea and many other common ailments veterans and civilians face.
  • Thats why The Cake House works diligently every day to provide veterans alternative solutions to combat different types of chronic ailments.
  • The Cake House is playing a major role in reducing these numbers by supplying safe, clinical prescription, over-the-counter cannabis and hemp-based medications to reduce pain, addiction and deaths.

Alsana® Expands Eating Disorder Treatment in the Greater St. Louis Area with the Opening of its seventh Residential Treatment Center

Thursday, July 22, 2021 - 1:52pm

"Juneberry's clinical team is committed to delivering evidence-based, compassionate care that facilitates healing in all areas of our clients' lives.

Key Points: 
  • "Juneberry's clinical team is committed to delivering evidence-based, compassionate care that facilitates healing in all areas of our clients' lives.
  • "Alsana's treatment programs reflect our strong commitment to meeting clients where they are in their eating disorder recoveries," said Gayle Devin, CEO for Alsana.
  • Eating disorder treatment professionals are invited to take part in Alsana's Juneberry Opening Celebration on July 29.
  • Alsana is an eating recovery community that offers holistic, compassionate treatment that focuses on the total health and overall wellness of each individual client.

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

Wednesday, July 21, 2021 - 1:30pm

The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.

Key Points: 
  • The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.
  • Since the FDAs approval of AZSTARYS in March, the various teams across Corium have been working diligently to ready AZSTARYS for its U.S. launch.
  • We believe Corium has built a best-in-class commercial organization, and as a result, we expect the market potential for AZSTARYS will be maximized.
  • AZSTARYS is an FDA-approved, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years or older.

Nobu: A Mental Health App that Provides Everything You Need to Explore Your Thoughts, Emotions and Mental Health Goals.

Tuesday, July 20, 2021 - 2:00pm

In the wake of the COVID-19 pandemic, the need for mental health resources became even more urgent.

Key Points: 
  • In the wake of the COVID-19 pandemic, the need for mental health resources became even more urgent.
  • Left untreated, mental health symptoms can negatively impact nearly all aspects of a person's life.
  • Nobu will help more people to get the help they need to take good care of their mental health, regardless of where they live.
  • Advanced Recovery Systems (ARS) is an integrated behavioral health care management company dedicated to the treatment of addiction, substance abuse and mental health conditions.

Neuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Tuesday, July 20, 2021 - 1:30pm

MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc.(NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.

Key Points: 
  • MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc.(NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.
  • The Company will host a conference call to review its results at8:30 a.m. Eastern Timethe same day.
  • The conference call will be broadcast live in listen-only mode via a webcast on the Companys investor relations website at ir.neuronetics.com .
  • Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.

Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board

Tuesday, July 20, 2021 - 12:30pm

Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.

Key Points: 
  • Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.
  • Dr. Husain has published over 40 research papers investigating the neurobiology and associated clinical care of mood disorders.
  • Dr. Husains appointment is another important milestone in our journey to bring safer, more efficacious psychedelic-inspired mental illness treatments to the market.
  • Mindset was established in order to develop pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients

Tuesday, July 20, 2021 - 12:31pm

Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Key Points: 
  • Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • Braxia develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications

Monday, July 19, 2021 - 1:30pm

The company plans to initiate its pivotal program for LYN-005, designed as the first-ever oral, ultra-long-acting, extended-release therapy, in early 2022.

Key Points: 
  • The company plans to initiate its pivotal program for LYN-005, designed as the first-ever oral, ultra-long-acting, extended-release therapy, in early 2022.
  • Both studies will evaluate LYN-005 at weekly doses ranging from 2 to 6 mg risperidone daily.
  • These studies will support indications in schizophrenia, bipolar mania, and bipolar 1 disorder.
  • We are grateful to the FDA for their guidance as we design this pivotal program.